Invention Grant
US09125910B2 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
有权
1- [2-（2,4-二甲基苯基硫烷基） - 苯基]哌嗪作为具有组合的5-羟色胺再摄取的化合物，用于治疗认知障碍的5-HT3和5-HT1A活性
![1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment](/docs/US/2015-09-08/US09125910B2/abs.jpg.600x600.jpg)
- Patent Title: 1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment
- Patent Title (中): 1- [2-（2,4-二甲基苯基硫烷基） - 苯基]哌嗪作为具有组合的5-羟色胺再摄取的化合物，用于治疗认知障碍的5-HT3和5-HT1A活性
-
Application No.: US14481000Application Date: 2014-09-09
-
Publication No.: US09125910B2Publication Date: 2015-09-08
- Inventor: Benny Bang-Andersen , Arne Mork , Tine Bryan Stensbol , Andre Faldt
- Applicant: H. Lundbeck A/S
- Applicant Address: DK Copenhagen-Valby
- Assignee: H. Lundbeck A/S
- Current Assignee: H. Lundbeck A/S
- Current Assignee Address: DK Copenhagen-Valby
- Agency: Fish & Richardson P.C.
- Priority: DK200600824 20060616; DK200601223 20060922; DK200601384 20061025; DK200700427 20070320
- Main IPC: A61K31/495
- IPC: A61K31/495 ; C07D295/096
![1-[2-(2,4 dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of cognitive impairment](/abs-image/US/2015/09/08/US09125910B2/abs.jpg.150x150.jpg)
Abstract:
This disclosure relates to a method of treating a disease selected from the group consisting of Alzheimer's disease, cognitive impairment, and attention deficit hyperactivity disorder (ADHD). The method includes administering a therapeutically effective amount of Compound I or a pharmaceutically acceptable salt thereof to patient in need thereof, in which Compound I is 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine.
Public/Granted literature
Information query
